// App-Quantinova.ai

e12050 : PIK3CA mutational status and correlation with tumor glycolysis imaged with [18F]FDG PET/CT in early primary ER+ / HER2- breast cancer patients: a feasibility study.

Researchers

Presenter

  • Heinrich Florian Magometschnigg

Principal Investigators

  • Anita Brandstetter

  • Martin Filipits

  • Margaretha Rudas

  • Peter Christian Dubsky

  • Georgios Karanikas

  • Katja Pinker-Domenig

Medical Centers

  • Dept. of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

  • 2Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • 2Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • Department of Pathology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • Department of Pathology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • Dept. of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • 18F-fluorodeoxyglucose

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved